Fact CheckerSign in

NCT05239468CompletedPhase 2

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis

Source: ClinicalTrials.gov · Last updated 16 Jul 2026

Brief summary (registry, in English)

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).

Status (registry)
Completed
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
72 (actual)
First submitted
28 Jan 2022
Start date
21 Mar 2022
Primary completion date
1 Sept 2025
Lead sponsor
Intercept Pharmaceuticals
NCT number
NCT05239468
EU CT number
2024-513584-77-00
EudraCT number
2022-001241-20

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 72
  • From 21 Mar 2022 to the primary completion date, 1 Sept 2025
  • 26 sites in 4 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • History or presence of other concomitant liver diseases
  • Treatment with commercially available OCA or participation in a previous study involving OCA, or other farnesoid X receptor (FXR) agonists, or peroxisome proliferator activated receptor (PPAR)-agonists within 3 months before Screening
  • Unable to tolerate BZF or other fibrates, treatment with commercially available fibrates, or participation in a previous study involving fibrate within 3 months before Screening.
    • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Other illness

  • Current or history of gallbladder disease

Lab values

  • If female, known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating

Other

  • Presence of clinical complications of PBC
  • History or presence of decompensating events

Who the study is looking for

  • A definite or probable diagnosis of PBC
  • Qualifying ALP and/or bilirubin liver biochemistry values
  • Taking ursodeoxycholic acid (UDCA) for at least 12 months or no UDCA for 3 months before Day 1

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (26)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital Italiano de Buenos Aires
Coordinator of this site? Confirm its status
Buenos AiresArgentinaUnknown status
Hospital Italiano La Plata
Coordinator of this site? Confirm its status
La PlataArgentinaUnknown status
Hospital Universitario Austral
Coordinator of this site? Confirm its status
PilarArgentinaUnknown status
DIM Clinical Privada
Coordinator of this site? Confirm its status
Ramos MejíaArgentinaUnknown status
Hospital Provincial del Centenario
Coordinator of this site? Confirm its status
RosarioArgentinaUnknown status
The Northern Alberta Clinical Trials and Research Centre
Coordinator of this site? Confirm its status
EdmontonCanadaUnknown status
University of Montreal
Coordinator of this site? Confirm its status
MontrealCanadaUnknown status
Pacific Gastroenterology Associates
Coordinator of this site? Confirm its status
VancouverCanadaUnknown status
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Coordinator of this site? Confirm its status
BolognaItalyCompleted
Piedmont Atlanta Hospital
Coordinator of this site? Confirm its status
AtlantaUnited StatesUnknown status
University of Alabama at Birmingham
Coordinator of this site? Confirm its status
BirminghamUnited StatesUnknown status
Beth Israel Deaconess Medical Center Harvard Liver Research Center
Coordinator of this site? Confirm its status
BostonUnited StatesUnknown status
University Hospitals Cleveland Medical Center*
Coordinator of this site? Confirm its status
ClevelandUnited StatesUnknown status
Gastro One
Coordinator of this site? Confirm its status
CordovaUnited StatesUnknown status
Southern California Gastrointestinal (GI) and Liver Centers (SCLC) - Coronado
Coordinator of this site? Confirm its status
CoronadoUnited StatesUnknown status
Methodist Clinical Research Institute (CRI)
Coordinator of this site? Confirm its status
DallasUnited StatesUnknown status
Houston Methodist Cancer Center
Coordinator of this site? Confirm its status
HoustonUnited StatesUnknown status
Gastrointestinal Associates of Northeast Tennessee
Coordinator of this site? Confirm its status
Johnson CityUnited StatesUnknown status
Loyola University Medical Center
Coordinator of this site? Confirm its status
MaywoodUnited StatesUnknown status
Schiff Center for Liver Diseases/University of Miami
Coordinator of this site? Confirm its status
MiamiUnited StatesUnknown status
Facey Medical Group
Coordinator of this site? Confirm its status
Mission HillsUnited StatesUnknown status
Ochsner Medical Center
Coordinator of this site? Confirm its status
New OrleansUnited StatesUnknown status
NYU Langone Medical Center
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
Wake Endoscopy Center
Coordinator of this site? Confirm its status
RaleighUnited StatesUnknown status
American Research Corporation at the Texas Liver Institute
Coordinator of this site? Confirm its status
San AntonioUnited StatesUnknown status
Tampa General Medical Group
Coordinator of this site? Confirm its status
TampaUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.